110 related articles for article (PubMed ID: 11454467)
1. Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates.
Kratz F; Drevs J; Bing G; Stockmar C; Scheuermann K; Lazar P; Unger C
Bioorg Med Chem Lett; 2001 Aug; 11(15):2001-6. PubMed ID: 11454467
[TBL] [Abstract][Full Text] [Related]
2. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
Mansour AM; Drevs J; Esser N; Hamada FM; Badary OA; Unger C; Fichtner I; Kratz F
Cancer Res; 2003 Jul; 63(14):4062-6. PubMed ID: 12874007
[TBL] [Abstract][Full Text] [Related]
3. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
4. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
5. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
Kratz F; Warnecke A; Scheuermann K; Stockmar C; Schwab J; Lazar P; Drückes P; Esser N; Drevs J; Rognan D; Bissantz C; Hinderling C; Folkers G; Fichtner I; Unger C
J Med Chem; 2002 Dec; 45(25):5523-33. PubMed ID: 12459020
[TBL] [Abstract][Full Text] [Related]
6. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
[TBL] [Abstract][Full Text] [Related]
8. Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis.
Bae M; Cho S; Song J; Lee GY; Kim K; Yang J; Cho K; Kim SY; Byun Y
Drugs Exp Clin Res; 2003; 29(1):15-23. PubMed ID: 12866360
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase targeted peptide vesicles for delivering anticancer drugs.
Bhunia D; Pradhan K; Das G; Ghosh S; Mondal P; Ghosh S
Chem Commun (Camb); 2018 Aug; 54(67):9309-9312. PubMed ID: 30070277
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.
Albright CF; Graciani N; Han W; Yue E; Stein R; Lai Z; Diamond M; Dowling R; Grimminger L; Zhang SY; Behrens D; Musselman A; Bruckner R; Zhang M; Jiang X; Hu D; Higley A; Dimeo S; Rafalski M; Mandlekar S; Car B; Yeleswaram S; Stern A; Copeland RA; Combs A; Seitz SP; Trainor GL; Taub R; Huang P; Oliff A
Mol Cancer Ther; 2005 May; 4(5):751-60. PubMed ID: 15897239
[TBL] [Abstract][Full Text] [Related]
11. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
[TBL] [Abstract][Full Text] [Related]
12. A macromolecular prodrug of doxorubicin conjugated to a biodegradable cyclotriphosphazene bearing a tetrapeptide.
Kim JK; Toti US; Song R; Sohn YS
Bioorg Med Chem Lett; 2005 Aug; 15(15):3576-9. PubMed ID: 15982876
[TBL] [Abstract][Full Text] [Related]
13. Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9.
Kline T; Torgov MY; Mendelsohn BA; Cerveny CG; Senter PD
Mol Pharm; 2004 Jan; 1(1):9-22. PubMed ID: 15832497
[TBL] [Abstract][Full Text] [Related]
14. Relationship between matrix metalloproteinase 2 and lung cancer progression.
Guo CB; Wang S; Deng C; Zhang DL; Wang FL; Jin XQ
Mol Diagn Ther; 2007; 11(3):183-92. PubMed ID: 17570740
[TBL] [Abstract][Full Text] [Related]
15. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting.
Terada T; Iwai M; Kawakami S; Yamashita F; Hashida M
J Control Release; 2006 Apr; 111(3):333-42. PubMed ID: 16488046
[TBL] [Abstract][Full Text] [Related]
16. N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity.
Fernandez AM; Van Derpoorten K; Dasnois L; Lebtahi K; Dubois V; Lobl TJ; Gangwar S; Oliyai C; Lewis ER; Shochat D; Trouet A
J Med Chem; 2001 Oct; 44(22):3750-3. PubMed ID: 11606140
[TBL] [Abstract][Full Text] [Related]
17. Recombinant snake venom metalloproteinase inhibitor BJ46A inhibits invasion and metastasis of B16F10 and MHCC97H cells through reductions of matrix metalloproteinases 2 and 9 activities.
Ji MK; Shi Y; Xu JW; Lin X; Lin JY
Anticancer Drugs; 2013 Jun; 24(5):461-72. PubMed ID: 23442578
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin.
Kratz F; Beyer U; Collery P; Lechenault F; Cazabat A; Schumacher P; Falken U; Unger C
Biol Pharm Bull; 1998 Jan; 21(1):56-61. PubMed ID: 9477169
[TBL] [Abstract][Full Text] [Related]
19. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy.
Kratz F; Müller-Driver R; Hofmann I; Drevs J; Unger C
J Med Chem; 2000 Apr; 43(7):1253-6. PubMed ID: 10753462
[No Abstract] [Full Text] [Related]
20. In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.
Ryppa C; Mann-Steinberg H; Fichtner I; Weber H; Satchi-Fainaro R; Biniossek ML; Kratz F
Bioconjug Chem; 2008 Jul; 19(7):1414-22. PubMed ID: 18578486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
